{"url_path":"/sec/psnl/8-k/2026-05-20/item-8-01","section_key":"item-8-01","section_title":"Item 8.01 Other Events.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-20","source_url":"https://www.sec.gov/Archives/edgar/data/1527753/0001193125-26-232533-index.html","accession_number":"0001193125-26-232533","cik":"0001527753","ticker":"PSNL","issuer_name":"Personalis, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1527753/0001193125-26-232533-index.html","primary_entity_key":"0001527753","primary_entity_name":"Personalis, Inc."},"word_count":101,"has_tables":true,"body_markdown":"Item 8.01 Other Events.\n\nOn May19, 2026, the Centers for Medicare & Medicaid Services Molecular Diagnostics Program expanded Medicare coverage for Personalis, Inc.’s ultrasensitive NeXT Personal® test to include monitoring treatment response to neoadjuvant therapy (NAT) in patients diagnosed with Stage II-III Triple-Negative Breast Cancer (TNBC) or HER2-positive (HER2+) breast cancer.\n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\nDate: May 20, 2026\n\nPersonalis, Inc.\n\n \n\nBy:\n\n/s/ Aaron Tachibana\n\nAaron Tachibana\n\nChief Financial Officer and Chief Operating Officer"}